Description

Qiagen Is Attracting Billion-Dollar Takeover Interest!

Qiagen has once again become the center of takeover speculation after reports indicated that private-equity firms EQT, Advent International, and KKR had shown early interest in the molecular-testing company. The stock jumped 11% on the report, reflecting investor expectations that competition among financial or strategic buyers could produce an acquisition premium. Yet the appeal of Qiagen is not based on rapid headline growth. The company recently lowered its 2026 sales outlook after immigration-related tuberculosis testing declined and U.S. research customers remained cautious. What buyers may instead see is a collection of valuable laboratory platforms, recurring consumable sales, resilient operating margins, and exposure to cancer research, infectious-disease testing, precision medicine, and genomic data analysis. Qiagen is already working with Moelis and Goldman Sachs on a strategic review, while its board is also conducting a CEO succession process.